Papers/PMID:40747302
Efficacy and safety of tirzepatide for weight loss in patients with obesity or type 2 diabetes: a systematic review and meta-analysis.
Frontiers in endocrinology2025The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
tirzepatide — decreases body mass
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×2“Pooled analysis demonstrated a reduction in body weight in patients receiving tirzepatide comparing with placebo (WMD=-10.80, 95%CI:-10.80 to -9.99, p < 0.00001), indicating a substantial effect of the treatment.”
Quoted verbatim from Efficacy and safety of tirzepatide for weight loss in patients with obesity or type 2 diabetes: a systematic review and meta-analysis.. - Study
- meta-analysis
- Dose
- 5, 10 or 15 mg once weekly
- Population
- Adults with obesity or type 2 diabetes in placebo-controlled phase 1 to 3 trials, pooled across 5, 10 and 15 mg doses
Efficacy and safety of tirzepatide for weight loss in patients with obesity or type 2 diabetes: a systematic review and meta-analysis.2025PMID:40747302Permalink